Cynosure (CYNO) PT Bumped to $45 at Leerink Partners
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Cynosure Announces Second-Quarter 2015 Results; Record Revenue of $83.7 Million, Up 15 Percent from Prior Year
July 28, 2015 8:00 AM EDTWESTFORD, Mass., July 28, 2015 /PRNewswire/ --Â Cynosure, Inc. (Nasdaq: CYNO), which designs, manufactures and markets medical devices for aesthetic procedures and precision surgical applications worldwide, today reported financial results for the three months ended June 30, 2015.
"Our North American business posted another quarter of double-digit growth, as revenues increased 47 percent year-over-year and selling prices remained stable," said Cynosure Chief Executive Officer Michael Davin. "While our international results reflected the economic slowdowns in Europe and China, as well as unfavorable foreign currency... More
